title: Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group.
abstract: OBJECTIVE
  This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy.
  
  
  METHODS
  Patients who enrolled in the SWOG 9326 study from September 1993 to July 1997 were required to have documented cCR from stage III ovarian cancer following front-line platinum-based therapy. Treatment consisted of 6 months of oral altretamine at 260 mg/m(2)/day for 14 consecutive days of a 28-day cycle.
  
  
  RESULTS
  Ninety-seven of 112 enrolled patients were evaluable for efficacy. This report presents median 6.2-year follow-up, dating from study registration. Median PFS was 28 (95% CI: 19-43) months. Median PFS for patients with optimal disease was 45 (95% CI: 27-48) months and for patients with suboptimal disease was 17 (95% CI: 12-26) months. Twenty-six of 61 (43%) patients with optimally debulked lesions and 5 of 36 (14%) patients with suboptimally debulked lesions remained disease free. Median survival of patients with optimally debulked disease has not been reached; median survival of patients with suboptimally debulked disease was 39 (95% CI: 19-51) months. No treatment-related adverse events were reported during the follow-up period.
  
  
  CONCLUSIONS
  Consolidation therapy with oral altretamine was generally well tolerated and associated with prolonged progression-free and overall survival in the Phase II setting.
authors.affiliation: University of Arizona Cancer Center, 1515 North Campbell Avenue, PO Box 245024, Tucson, AZ 85724-5024, USA. dalberts@azcc.arizona.edu
authors.forename: D S
authors.initials: DS
authors.lastname: Alberts
authors.forename: C
authors.initials: C
authors.lastname: Jiang
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: S
authors.initials: S
authors.lastname: Wilczynski
authors.forename: M
authors.initials: M
authors.lastname: Markman
authors.forename: M L
authors.initials: ML
authors.lastname: Rothenberg
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006585:Altretamine / Q000008:administration & dosage*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D016879:Salvage Therapy; D015206:Southwestern United States; D016019:Survival Analysis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D006585:Altretamine